Literature DB >> 19830028

Metastatic adenocarcinoma within a functioning adrenal adenoma: a case report.

Jeremiah T Martin1, Fuad Alkhoury, Scott Helton, Paul Fiedler, Olga Sakharova, Steven Yood.   

Abstract

We present the case of a 54-year-old woman who underwent right adrenalectomy for palliation of Cushing's symptoms. She had recently been diagnosed with lung adenocarcinoma. Pathologic findings revealed a 5 cm adrenal adenoma with a metastatic adenocarcinoma deposit. The occurrence of tumor-to-tumor metastasis is rare, and the finding of a metastasis within a functional adrenal adenoma exceptionally so. Previously reported incidences of this finding in patients with lung cancer range from 0.14% to 0.63%. We review the literature regarding this unusual finding.

Entities:  

Year:  2009        PMID: 19830028      PMCID: PMC2740135          DOI: 10.4076/1757-1626-2-7965

Source DB:  PubMed          Journal:  Cases J        ISSN: 1757-1626


Introduction

Tumor-to-tumor metastasis is an infrequent occurrence. Here we report on the finding of metastatic lung adenocarcinoma within a functioning adrenal adenoma which was excised for palliation of Cushing’s symptoms in a 54-year-old female.

Case presentation

A 54-year-old Caucasian American female who previously had a hiatal hernia repair was referred for abdominal CT scan after operative findings of hepatomegaly were noted. On CT (Figure 1) and subsequent MRI a 4 cm right adrenal adenoma with benign radiologic characteristics was noted. Over the preceeding two years the patient had symptoms consistent with Cushing’s syndrome with complaints of weight gain, lower extremity swelling and muscle weakness. Workup revealed an elevated free urinary cortisol (195 µg/day), suppressed ACTH (<5 pg/mL) consistent with adrenal Cushing’s syndrome. She was scheduled for laparoscopic adrenalectomy, however a liver lesion was found at laparoscopy which, on biopsy, was positive for metastatic adenocarcinoma of pulmonary origin. The procedure was terminated at this point for further patient counseling. Upon the patient’s insistence, she was again scheduled for adrenalectomy to control her Cushing’s symptoms prior to undergoing therapy for her lung cancer.
Figure 1.

Abdominal CT scan, arrow depicts right adrenal mass.

Abdominal CT scan, arrow depicts right adrenal mass. At laparoscopy, a 5 × 4 × 4 cm, 45 g right adrenal mass was identified and removed without complication (Figure 1). The patient recovered well and was commenced on supplementary corticosteroids. Final pathology revealed an adrenal cortical adenoma with a focus of adenocarcinoma, positive for cytokeratin 7 and TTF-1, an immunophenotype consistent with lung primary (Figures 2-6).
Figure 2.

Gross Photo shows yellow adrenal cortical adenoma with small, gray focus slightly left of center representing metastatic adenocarcinoma.

Figure 6.

Cytokeratin 7 immunostain demonstrates cytoplasmic positivity of adenocarcinoma, consistent with lung origin.

Gross Photo shows yellow adrenal cortical adenoma with small, gray focus slightly left of center representing metastatic adenocarcinoma. Photomicrograph shows metastatic adenocarcinoma on the left and adrenal cortical adenoma on the right (H&E stain - Low Power). Photomicrograph shows malignant glands (adenocarcinoma) intermixed with foamy adrenal cortical adenoma cells (H&E stain - High Power). TTF-1 immunostain demonstrates nuclear positivity of adenocarcinoma, consitent with lung origin. Cytokeratin 7 immunostain demonstrates cytoplasmic positivity of adenocarcinoma, consistent with lung origin.

Discussion

The occurrence of adrenal metastasis in the setting of non-small cell lung cancer (NSCLC) is not uncommon. In patients with NSCLC, the incidence has been reported from 25-40% during the course of the disease [1,2]. Adrenal metastases likely develop via lymphatic spread in early disease and via hematogenous spread in more advanced disease. This is evidenced by a greater propensity towards ipsilateral metastasis early in the disease course, with contralateral or bilateral metastases more likely to occur with advanced disease [2]. Despite the relative frequency of adrenal metastasis, this finding in the setting of an adrenal adenoma is rare. This phenomenon has been studied by Moriya et. al who noted a 0.63% incidence of metastasis to an adrenal adenoma in a review of lung cancer autopsy cases [3]. This compares with an incidence of 0.14% found by Onuigbo et al. in a review of 7232 lung cancers [4]. The statistical analysis of Moriya’s group indicated that there was a propensity for lung cancer to metastasize to an adrenal adenoma if present. Tumor-to-tumor metastasis is an uncommon occurrence, and has only been documented in sporadic case reports and series since 1902 [5]. Fewer than 100 cases have been reported in the literature. Our institution previously reported a case of a colonic adenocarcinoma metastasizing to a thyroid adenoma [6]. The phenomenon generally involves metastasis from a donor (malignant) tumor to either a benign or malignant recipient tumor. Lung cancer is the most common primary tumor involved in up to 50% of the reported cases [7]. Other donor tumors which have been reported include breast, gastrointestinal, prostate and thyroid malignancies. The most frequent benign recipient is meningioma [8] with renal cell carcinoma being the most common malignant recipient [9]. Generally, the presence of an adrenal metastasis in the setting of lung cancer classifies the patient as having Stage IV disease and therefore benefiting most from chemotherapy. There is some evidence that patients with otherwise surgically resectable lung cancer and documented isolated adrenal metastasis may benefit from simultaneous resection [10]. This diagnosis can be difficult to determine preoperatively as it is far more likely for a screening CT scan to reveal an incidental adenoma. That said, thorough inspection of any adenoma with chemical shift imaging on MRI can with some confidence determine whether or not a mass is completely benign [11]. Given the high incidence of adrenal metastasis over the course of NSCLC, regular screening should include careful follow up of any adrenal masses. Metachronous adrenal masses should be resected when there is suspicion of adrenal metastasis in the setting of adrenal enlargement or cytologic confirmation [12]. The authors are not aware of other cases of NSCLC metastasis to a functioning adrenal adenoma. Tumor-to-tumor metastasis has been reported in the setting of a non-functioning adenoma [11]. The primary indication for adrenalectomy in our patient was to palliate her from Cushing’s symptoms. Following resection of her tumor she underwent adjuvant therapy for her lung cancer. Early identification of adrenal metastases is essential as adrenalectomy may improve survival in selected patients. To this end, physicians caring for patients with lung cancer must maintain a high index of suspicion to detect these lesions.
  11 in total

1.  LUNG CANCER METASTASIS TO ADRENAL CORTICAL ADENOMAS.

Authors:  W I ONUIGBO
Journal:  J Pathol Bacteriol       Date:  1963-10

2.  Metastatic adenocarcinoma within an adrenal adenoma: detection with chemical shift imaging.

Authors:  R Y Shifrin; R E Bechtold; E S Scharling
Journal:  AJR Am J Roentgenol       Date:  1996-10       Impact factor: 3.959

3.  Do adrenal metastases from lung cancer develop by lymphogenous or hematogenous route?

Authors:  P Károlyi
Journal:  J Surg Oncol       Date:  1990-03       Impact factor: 3.454

Review 4.  Tumour-to-tumour metastasis. A report of two unusual autopsy cases.

Authors:  K Honma; K Hara; T Sawai
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

Review 5.  Tumor-to-tumor metastasis to a thyroid follicular adenoma as the initial presentation of a colonic adenocarcinoma.

Authors:  Oluwole Fadare; Vinita Parkash; Paul N Fiedler; Adam B Mayerson; Bolanle Asiyanbola
Journal:  Pathol Int       Date:  2005-09       Impact factor: 2.534

6.  Metachronous adrenal masses in resected non-small cell lung cancer patients: therapeutic implications of laparoscopic adrenalectomy.

Authors:  Marco Lucchi; Paolo Dini; Marcello Carlo Ambrogi; Piero Berti; Gabriele Materazzi; Paolo Miccoli; Alfredo Mussi
Journal:  Eur J Cardiothorac Surg       Date:  2005-05       Impact factor: 4.191

7.  Tumor-to-tumor metastasis: report of 2 cases of metastatic carcinoma to angiomyolipoma of the kidney.

Authors:  Reva Ricketts; Pheroze Tamboli; Bogdan Czerniak; Charles C Guo
Journal:  Arch Pathol Lab Med       Date:  2008-06       Impact factor: 5.534

Review 8.  Surgical management of adrenal metastases from lung cancer.

Authors:  A L Beitler; J D Urschel; S R Velagapudi; H Takita
Journal:  J Surg Oncol       Date:  1998-09       Impact factor: 3.454

9.  Lung cancer metastasis to adrenocortical adenomas. A chance occurrence or a predilected phenomenon?

Authors:  T Moriya; T Manabe; K Yamashita; S Arita
Journal:  Arch Pathol Lab Med       Date:  1988-03       Impact factor: 5.534

10.  Large bilateral adrenal metastases in non-small cell lung cancer.

Authors:  Charisios Karanikiotis; Apostolos Anto Tentes; Sotirios Markakidis; Konstantinos Vafiadis
Journal:  World J Surg Oncol       Date:  2004-11-13       Impact factor: 2.754

View more
  4 in total

1.  Metastasis of carcinoma of the lung to a carotid body paraganglioma.

Authors:  Yvonne Bury; Richard Green; Mona Jain; James Moor
Journal:  BMJ Case Rep       Date:  2012-04-04

2.  Tumor-to-tumor metastasis from lung cancer: a clinicopathological postmortem study.

Authors:  Susumu Matsukuma; Takako Kono; Hiroaki Takeo; Yusuke Hamakawa; Kimiya Sato
Journal:  Virchows Arch       Date:  2013-08-03       Impact factor: 4.064

3.  Pulmonary miliary papillary/micropapillary adenocarcinoma manifesting as carcinomatous encephalitis.

Authors:  P Vaideeswar; S S Nayak; A Verma; N A Goel
Journal:  J Postgrad Med       Date:  2017 Jul-Sep       Impact factor: 1.476

4.  Lung adenocarcinoma metastasizing to fibrous histiocytoma: A case report.

Authors:  Yang Liu; Bing Dai
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.